The commercialization dawn of mRNA cancer vaccines is emerging, heralding a reassessment of industrial chain value.

On August 19, 2026, Moderna and Merck announced successful results from a Phase III clinical trial of their mRNA cancer vaccine—combined with Keytruda—in the adjuvant treatment of high-risk melanoma following surgery. This marks the world’s first successful Phase III trial for an mRNA cancer vaccine, validating the feasibility of mRNA technology in oncology and representing a major milestone toward commercialization. Moderna’s stock surged 177% in a single day, instantly igniting the global capital markets’ mRNA sector. In the field of mRNA cancer therapeutics, beyond global leaders Moderna and BioNTech, numerous Chinese companies—including Yunding Xinyao, Abogen Biosciences, Likang Life Sciences, and Sioda Biotech—are also actively engaged, with related pipeline candidates currently in Phase I or II clinical trials. Meanwhile, several firms originally focused on mRNA COVID-19 vaccine development are either expanding into or entering the mRNA cancer vaccine space through alternative strategies. Additionally, upstream suppliers of mRNA drug raw materials—such as Jinkai Technology and Nearshore Protein—stand to benefit directly.

BioNTech’s three manufacturing facilities remain unsold—what does this signal about the ultimate fate of COVID-19 mRNA production capacity?

The problem lies in the present. Demand for Comirnaty has declined from its peak to a steady-state level, and mRNA production capacity is highly specialized: fermentation, purification, lipid nanoparticle (LNP) encapsulation, and fill-finish lines are all specifically engineered for nucleic acid-based processes. Retrofitting these facilities for antibody or small-molecule drug manufacturing would cost nearly as much as building new plants. Why aren’t buyers bidding? Prospective acquirers are running different calculations. The European biotech funding winter has yet to end; cash-strapped companies hesitate to assume fixed-cost liabilities. Large pharmaceutical companies with existing vaccine pipelines still have idle internal capacity and thus lack incentive to pay a premium for second-hand equipment. BioNTech’s own financial reports illustrate the scale of its capacity pressure. Total revenue has dropped from hundreds of millions of euros at the pandemic peak to tens of millions of euros over the past two years. Management has fully pivoted its strategic focus toward oncology pipelines—including the personalized neoantigen vaccine BNT122, developed in collaboration with Roche. This contraction extends beyond production capacity alone. Over the past two years, BioNTech has progressively implemented cost-cutting measures—including workforce reductions and asset disposals—and the recent closure of three manufacturing sites represents a logical continuation of that strategy: removing all non-core assets from its balance sheet. mRNA isn’t exiting—excess hardware is A clear boundary must be drawn. Closing surplus capacity does not equate to abandoning mRNA technology. BioNTech retains its Mainz-based infrastructure, which continues to support process development and small-to-medium-scale manufacturing for its RSV, influenza, and oncology vaccine pipelines. What is being cut is redundant capacity—not the underlying technology platform. This distinction is critical. The scientific value of mRNA has not diminished with the waning of the pandemic; rather, what has disappeared is the rationale for heavy-capital investment in manufacturing facilities built in anticipation of imagined explosive demand. In fact, with the recent regulatory approval of mRNA-based influenza vaccines and breakthrough progress in mRNA cancer vaccines, mRNA technology is re-emerging center stage. The reckoning for Chinese mRNA companies China’s mRNA industrial chain likewise underwent a capacity-building race during the pandemic. Companies such as StemiRNA Therapeutics and Abogen Biosciences planned and constructed large-scale manufacturing facilities, while Sinopharm Group and Walvax Biotechnology also entered the development of COVID-19 mRNA vaccines.